

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF THE GROUP'S "RIVAROXABAN TABLETS"

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Rivaroxaban Tablets (10mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China, being the second generic drug of this type granted approval and deemed as passing the consistency of quality and efficacy evaluation in China.

Rivaroxaban is an anticoagulant medication used for 1) prevention of venous thromboembolism in adult patients scheduled for hip or knee joint replacement surgery; 2) treatment of deep vein thrombosis and pulmonary embolism in adults, reducing the risk of recurrence 6 months after initial treatment; 3) reduction in risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation exposed to one or multiple risk factors such as congestive heart failure, hypertension, ≥ 75 years of age, diabetes or history of stroke or transient ischemic attack.

The Product is an oral anticoagulant that directly inhibits factor Xa with advantages of good clinical efficacy, convenience of drug administration, no requirement for dose adjustments and routine monitoring, providing patients with another medication option for prevention and treatment of thrombotic diseases. The approval of the Product further enriches the Group’s product portfolio in the cardiovascular field and also provides a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 9 March 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

* *For identification purpose only*